The purpose of this study is to assess the drug levels, safety, and tolerability of cendakimab in healthy male and female Chinese participants.

Inclusion Criteria:

• Participants must be Chinese (both biological parents are ethnically Chinese).
• Body mass index (BMI) of 18.0 through 28.0 kilograms/meter squared (kg/m^2), inclusive. BMI = weight (kg)/[height (m)]^2.
• Body weight ≥ 50.0 kg.

Exclusion Criteria:

• History of clinically significant infection within 4 weeks of dosing on Day 1.
• Significant medical history/condition, laboratory abnormality, or psychiatric illness that would prevent the participant from participating in the study.
• Condition(s) which may confound the ability to interpret data from the study, as determined by the investigator.

Other protocol-defined inclusion/exclusion criteria apply.